title: Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.
authors.forename: Jesse D
authors.initials: JD
authors.lastname: Raffa
authors.forename: Harout K
authors.initials: HK
authors.lastname: Tossonian
authors.forename: Jason
authors.initials: J
authors.lastname: Grebely
authors.forename: A John
authors.initials: AJ
authors.lastname: Petkau
authors.forename: Stanley
authors.initials: S
authors.lastname: DeVlaming
authors.forename: Brian
authors.initials: B
authors.lastname: Conway
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002170:Canada; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D006678:HIV / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D008875:Middle Aged; D008962:Models, Theoretical; D009154:Mutation; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012189:Retrospective Studies; D019562:Viral Load
chemical_list: D012367:RNA, Viral; D008691:Methadone